ViroPharma's Phase III transplant drug study fails endpoint - Pharmaceutical Business Review PDF Print

... III trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant patients did not achieve its primary endpoint. ...

read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.